HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.

AbstractBACKGROUND:
In the ALL-BFM 95 trial for treatment of acute lymphoblastic leukemia, response to a prednisone pre-phase (prednisone response) was used for risk stratification in combination with age and white blood cell count at diagnosis, response to induction therapy and specific genetic high-risk features.
DESIGN AND METHODS:
Cytomorphological marrow response was prospectively assessed on Day 15 during induction, and its prognostic value was analyzed in 1,431 patients treated on ALL-BFM 95.
RESULTS:
The 8-year probabilities of event-free survival were 86.1%, 74.5%, and 46.4% for patients with M1, M2, and M3 Day 15 marrows, respectively. Compared to prednisone response, Day 15 marrow response was superior in outcome prediction in precursor B-cell and T-cell leukemia with, however, a differential effect depending on blast lineage. Outcome was poor in T-cell leukemia patients with prednisone poor-response independent of Day 15 marrow response, whereas among patients with prednisone good-response different risk groups could be identified by Day 15 marrow response. In contrast, prednisone response lost prognostic significance in precursor B-cell leukemia when stratified by Day 15 marrow response. Age and white blood cell count retained their independent prognostic effect.
CONCLUSIONS:
Selective addition of Day 15 marrow response to conventional stratification criteria applied on ALL-BFM 95 (currently in use in several countries as regular chemotherapy protocol for childhood acute lymphoblastic leukemia) may significantly improve risk-adapted treatment delivery. Even though cutting-edge trial risk stratification is meanwhile dominated by minimal residual disease evaluation, an improved conventional risk assessment, as presented here, could be of great importance to countries that lack the technical and/or financial resources associated with the application of minimal residual disease analysis.
AuthorsMelchior Lauten, Anja Möricke, Rita Beier, Martin Zimmermann, Martin Stanulla, Barbara Meissner, Edelgard Odenwald, Andishe Attarbaschi, Charlotte Niemeyer, Felix Niggli, Hansjörg Riehm, Martin Schrappe
JournalHaematologica (Haematologica) Vol. 97 Issue 7 Pg. 1048-56 (Jul 2012) ISSN: 1592-8721 [Electronic] Italy
PMID22271901 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers
  • Cytarabine
  • Vincristine
  • Cyclophosphamide
  • Prednisolone
  • Mercaptopurine
  • Asparaginase
  • Prednisone
  • Daunorubicin
Topics
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
  • Asparaginase (administration & dosage)
  • Biomarkers (analysis)
  • Bone Marrow (drug effects, pathology)
  • Child
  • Child, Preschool
  • Cyclophosphamide (administration & dosage)
  • Cytarabine (administration & dosage)
  • Daunorubicin (administration & dosage)
  • Disease-Free Survival
  • Female
  • Humans
  • Infant
  • Lymphocyte Count
  • Male
  • Mercaptopurine (administration & dosage)
  • Neoplasm, Residual
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (diagnosis, drug therapy, mortality)
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (diagnosis, drug therapy, mortality)
  • Prednisolone (administration & dosage)
  • Prednisone (administration & dosage)
  • Prognosis
  • Prospective Studies
  • Remission Induction
  • Risk Assessment
  • Treatment Outcome
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: